Protamine News and Research

RSS
Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Pradaxa use does not appear to increase serious bleeding

Pradaxa use does not appear to increase serious bleeding

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

New nano-systems capable of binding heparin as effectively as protamine

New nano-systems capable of binding heparin as effectively as protamine

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

Further evidence on adverse effects of smoking on fertility

Further evidence on adverse effects of smoking on fertility

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

Cardiva Medical, Advanced Vascular Dynamics sign agreement to distribute hemostasis products

Cardiva Medical, Advanced Vascular Dynamics sign agreement to distribute hemostasis products

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Protein vaccines for needle-free immunization through the skin

Protein vaccines for needle-free immunization through the skin

Novo Nordisk awarded contract by VA as primary source provider of insulin

Novo Nordisk awarded contract by VA as primary source provider of insulin

New guidelines on the management of antithrombotic agents for endoscopic procedures published

New guidelines on the management of antithrombotic agents for endoscopic procedures published

Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven

Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven

Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen

Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen